Statistics from Altmetric.com
Non-steroidal anti-inflammatory drugs (NSAIDs) are a cornerstone of the treatment of mild to moderate pain and are frequently used on a long-term basis for patients with arthritis. In 2004, rofecoxib, a cyclooxygenase-2 (COX-2) inhibitor, was removed from the market because of an increased risk of cardiovascular events associated with the drug.1 Subsequently, concern has grown about the cardiovascular safety of COX-2 inhibitors and traditional non-selective NSAIDs.2 Multiple studies with varying outcomes have not yet answered which, if any, NSAIDs are safe from a cardiovascular standpoint.
This was a network meta-analysis that involved large-scale randomised controlled trials comparing any NSAID with other NSAIDs or placebo. Selected studies had at least two arms with at least 100 patient years of follow-up. Trials that involved cancer patients were excluded. Data were …
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.